The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.
The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.
Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.
The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.
Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.
Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.
Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.
The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.
A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.
A new vaginal swab test developed by molecular diagnostics company PinkDx may help women with abnormal bleeding detect endometrial cancer without undergoing a painful biopsy. The development comes as death rates from endometrial cancer, one of the most common cancers in women, are increasing.
Research shows that treatment with norrin helps maintain healthy blood vessels in the retina and preserves vision in diabetic rats, offering potential hope for treating diabetic retinopathy, a complication affecting over 100 million people in the U.S.
The University of California, San Francisco opened the MESSI-LEO Phase 1 trial on October 30, testing a wearable 128-element ultrasound headband that targets the caudate region of the brain to reduce auditory hallucinations in schizophrenia patients. The noninvasive treatment addresses persistent hallucinations that affect approximately 40% of patients despite antipsychotic medications.
An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.
A randomized clinical trial published in Clinical Infectious Diseases found that screening and treating pregnant patients for three common sexually transmitted infections twice during pregnancy was associated with a 23% lower risk of preterm birth compared with standard care.
Researchers from Rutgers and other universities analyzed hundreds of online reviews of lemborexant, a prescription insomnia medication, and found that approximately 25% of reviewers stopped or planned to stop taking the drug due to troubling side effects.
A novel allergen-specific, immune signature-directed diet (iDIET) led to significant improvements in histologic and endoscopic responses in patients with eosinophilic esophagitis compared with a sham elimination diet, according to results from a small randomized study presented in Nashville, Tennessee.
MIT researchers have demonstrated that tiny magnetic beads implanted in muscle tissue can accurately track muscle movement, offering a new method for controlling prosthetic limbs. The wireless system uses skin-mounted magnetometers to track the implanted beads, achieving precision that matches or exceeds traditional electromyography methods.
A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.
Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.
A clinical trial published in The BMJ found that commonly used injections for Achilles tendinopathy—including high-volume saline, local anesthetic, and low-dose corticosteroid—offer no meaningful clinical advantage over sham treatment. The findings add to ongoing controversy about corticosteroid injections for tendon conditions.
A phase 1/2 trial led by Roswell Park Comprehensive Cancer Center found that combining bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with metastatic clear-cell renal cell carcinoma, the most common type of kidney cancer. The study established a safe dosing regimen and demonstrated promising antitumor activity in treatment-naive patients.
Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.
A major trial published in JAMA shows that a simple adjustment to drugs given during operations for septic shock could prevent thousands of patients from suffering kidney damage. Scientists from the University of Southampton and Zhejiang University School of Medicine conducted the research.
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.
Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.
China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.
Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.
AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.
Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.
Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.
The Phase 2 BESTOW clinical trial demonstrated that tegoprubart, a novel anti-CD40L antibody therapy, was superior to tacrolimus, the current standard of care, at preserving kidney function in adults receiving their first kidney transplant. The trial results suggest a potential advancement in immunosuppressive treatment regimens for transplant patients.
A University of Michigan Rogel Cancer Center study found that online resources combined with phone-based coaching helped more eligible cancer patients complete genetic testing. About 10% of cancers are linked to inherited genetic variants, but as few as 1 in 15 eligible patients currently complete testing, with lack of knowledge being a key barrier.
Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.
Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.
Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.
Johnson & Johnson reported promising results from an early-stage clinical trial of its experimental oral prostate cancer treatment JNJ-6143, with 77% of patients with advanced prostate cancer experiencing significant drops in PSA levels after treatment. The trial involved patients who had undergone multiple prior treatments.
Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.
A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.
A recent clinical trial found that dietary acid reduction using base-producing fruits and vegetables is more effective than the standard oral sodium bicarbonate treatment for metabolic acidosis in people with chronic kidney disease. The findings will be presented at ASN Kidney Week.
The Treasury Department issued proposed rules that would severely restrict future US investment in Chinese biotechnology companies, potentially complicating financial ties as American drugmakers increasingly turn to China for clinical trials and manufacturing.
The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.
The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.
Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.
Rapport Therapeutics announced positive phase 2 results for RAP-219, an oral AMPA receptor modulator licensed from Johnson & Johnson, showing improvement in bipolar mania symptoms. This marks the company's second phase 2 success for the asset in 14 months.
A new study from the ARCTIC trial demonstrates that patients with early rheumatoid arthritis managed with a treat-to-target strategy achieved favorable long-term outcomes over 10 years. Patients who achieved sustained remission at two years showed higher remission rates and better physical function throughout the decade-long follow-up period.
A Columbia-led clinical trial published in JAMA found that opening blockages in the brain's main blood vessels through stenting or surgery does not improve cognitive function, despite hopes that improved blood flow would enhance cognition in patients with clogged carotid arteries.
The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) as monotherapy for adults with previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H status, based on interim phase 2 AZUR-1 trial results. This marks a first-in-class approval in this specific type of rectal cancer.
Gilead Sciences reported mid-stage study results showing its oral α4β7 inhibitor emvistegrast eliminated symptoms in patients with ulcerative colitis, with remission rates exceeding those of Entyvio. The company plans to begin late-stage trials in 2027.
Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.
French biotech Osivax announced that its lead influenza vaccine OVX836 did not meet its pre-specified primary endpoint in a Phase 2b trial, though the company reported a first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes. Osivax plans to advance a combination strategy for next-generation seasonal influenza vaccines.
A landmark study published in The New England Journal of Medicine found that continuous glucose monitoring devices benefit all type 2 diabetes patients, including those not taking insulin, with users achieving lower HbA1c levels and spending approximately 5 more hours per day in target glucose range. The Dexcom CONNECT study marks the first standalone real-time CGM clinical data published in NEJM in nearly two decades.
Vanda Pharmaceuticals' experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study in female patients, prompting the company to put the program on hold pending further analysis.
Verastem Oncology announced encouraging early results for its KRAS G12D inhibitor in pancreatic cancer patients alongside a $250 million fundraise and CEO departure, positioning itself as a competitor to Revolution Medicines in next-generation KRAS treatments.
The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.
Merck CEO Rob Davis said he expects the personalized cancer vaccine being developed with Moderna to have a shortened production timeline from its current six-week manufacturing period. The announcement comes after the companies reported promising late-stage trial results in August for the mRNA vaccine combined with immunotherapy for melanoma.
A newly announced clinical trial will test whether GLP-1 weight loss drugs can improve outcomes related to criminal justice system interactions, employment, and housing stability, expanding beyond existing trials examining the medications' effects on substance use disorders and other health conditions.
An investigational radiotracer test, iodine-124 evuzamitide PET/CT, demonstrated accurate diagnosis and quantification of cardiac amyloidosis in a single noninvasive scan, detecting early disease missed by other diagnostic methods. Results from the REVEAL study were presented at the Heart Failure Society of America Annual Scientific Meeting, with the test now headed for FDA review.
Prediction marketplaces are expanding into the pharmaceutical field, allowing users to buy and sell shares on clinical trial outcomes. Experts warn this development may threaten the integrity of drug trials as the platforms take their first steps into this new territory.
A study presented at a medical conference found that the GLP-1 medication semaglutide produces substantial weight loss in adolescents with obesity, with similar gastrointestinal side effects as seen in adults. However, researchers noted that trials in teens rarely assess critical developmental factors including bone density, lean mass, or neurodevelopment.
A randomized clinical trial found that adding metastasis-directed ablation (focused radiation or surgery) to first-line systemic therapy did not improve progression-free or overall survival in patients with oligometastatic breast cancer. Two-year overall survival was 88.4% with systemic therapy alone versus 78% with ablation added.
Zealand Pharma announced positive Phase 2 ZUPREME-2 trial results for its amylin analog petrelintide, which achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo in people with overweight or obesity and type 2 diabetes. The drug also demonstrated HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo.
Bangladesh is considering clinical trials for a dengue vaccine after hundreds of deaths and thousands of hospitalizations from the mosquito-borne disease. The outbreak has worsened through September, with at least 233 deaths reported and experts warning that weather conditions could fuel further spread.
A clinical trial of optogenetic therapy, based on Nobel Prize-winning research, demonstrated safety and partial vision restoration in patients with advanced retinitis pigmentosa, with 7 of 10 patients showing improved light sensitivity. The treatment uses gene therapy to engineer retinal cells to respond to light.
Epicrispr Biotechnologies presented encouraging updated findings from testing of its epigenetic editing treatment for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disease. The data builds the case for the company's therapeutic approach to treating the condition.
An investigational drug, z-basivarsen, demonstrated sustained improvements in myotonia, motor function, and strength in patients with myotonic dystrophy type 1, according to analysis from the ACHIEVE trial. The findings suggest potential therapeutic benefits for this genetic neuromuscular disorder.
The investigational triple agonist retatrutide demonstrated significant weight loss and improved glycemic control in adults with obesity and type 2 diabetes in the TRIUMPH-2 phase III trial, with some participants losing up to a quarter of their body weight. Results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.
Boehringer Ingelheim's investigational dual GIP/GLP-1 agonist survodutide achieved up to 9.8% weight loss in the phase 3 SYNCHRONIZE-2 trial for adults with type 2 diabetes and obesity, meeting primary endpoints but falling short of competing drugs. The results raised tolerability concerns and led to a drop in partner Zealand Pharma's stock.
The FDA has approved Bristol Myers Squibb's Camzyos (mavacamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients, making it the first cardiac myosin inhibitor approved for children with this painful heart condition. The approval is based on positive results from the Phase 3 SCOUT-HCM trial.
Pfizer's experimental eczema drug tilrekimig achieved significantly stronger skin clearance compared to placebo at multiple doses in a mid-stage clinical trial after 16 weeks. The company presented detailed Phase 2 results for the atopic dermatitis treatment.
Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.
UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.
Eli Lilly reported that its experimental triple-agonist drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, with more than half of patients dropping below the obesity threshold.
Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.
Three participants have died in clinical trials of Novartis' chimeric antigen receptor T-cell therapy for autoimmune disease, prompting physicians to approach patient discussions with greater caution as the field remains in early stages of development.
A clinical trial led by Queen Mary University of London has found that transcutaneous autonomic neuromodulation through the ear is safe, well-tolerated, and easy for patients with uncontrolled hypertension to use at home. The SCRATCH-HTN trial demonstrates the potential of this noninvasive technique as a treatment option for high blood pressure.
Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.
Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.
Otsuka Pharmaceutical and Ionis Pharmaceuticals announced their experimental drug ulefnersen met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS), showing improvements in functional impairment and survival. The partners plan to approach the FDA to determine potential regulatory pathways.
Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.
Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.
First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.
Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.
Novo Nordisk announced topline results showing CagriSema achieved 12.4% weight loss versus 9.1% for tirzepatide at 60 weeks in adults with type 2 diabetes in the REIMAGINE 5 trial, and induced 21% weight loss at 68 weeks in people with overweight or obesity without diabetes in the REDEFINE trial.
The FDA has granted breakthrough therapy designation to Definium Therapeutics' DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder.
Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.
A placebo-controlled trial demonstrated that intrauterine instillation of the anesthetic mepivacaine effectively reduces pain during intrauterine device (IUD) placement, particularly in nulliparous patients. The findings address growing patient reports of pain during IUD insertion procedures.
The IMpower030 trial showed that adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival in patients with stage IIB-IIIB resectable non-small cell lung cancer without EGFR mutations, but the drug missed its primary endpoint.
The FDA is accepting applications for a pilot program to expedite drug testing in humans, while at least 19 US states have applied for a Medicaid drug-pricing experiment with international benchmarking. Separately, India's government is streamlining its drug approval process by allowing studies to begin after notifying regulators and cutting import license processing times in half.
AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.
The FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000 (opakalim), pausing new patient enrollment in trials following concerning findings in rodent studies. The hold was announced weeks after Biohaven sold rights to the therapy.
AstraZeneca announced its experimental drug tozorakimab achieved approximately 30% reductions in moderate and severe COPD exacerbations compared to standard therapy in two late-stage studies presented at the European Respiratory Society Congress.
AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.
Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.
BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.
A clinical trial found that immediate coronary angiography did not improve 30-day survival rates compared to a deferred strategy in patients without ST-segment elevation on ECG following out-of-hospital cardiac arrest.
Novartis and Ionis's pelacarsen failed to protect heart health despite lowering Lp(a) levels in a large clinical trial, raising questions about the therapeutic approach and increasing pressure on Novartis's drug pipeline. Shares fell 3.3%.
Ultragenyx Pharmaceuticals' apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The failure of what was once considered a potential blockbuster therapy is forcing Ultragenyx to examine significant cost cuts.
AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.
Teva's experimental drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge in a mid-stage study, representing potential progress for a condition with no current drug treatments.
A non-invasive urine test being trialled by the NHS has been found to detect more than nine in ten bladder cancer cases in a study of 964 patients across seven NHS urology centers. The test, led by the University of Birmingham and Nonacus, could help reduce reliance on cystoscopies and waiting lists.
A clinical trial published in Lancet Infectious Diseases found that Paxlovid, an antiviral drug commonly used to treat acute COVID-19, does not alleviate long COVID symptoms when treatment is extended. The study involved 959 participants.
The FDA halted testing of Regenxbio's gene therapy for Hunter Syndrome after spinal MRI scans detected abnormalities in five trial participants. This is the second clinical hold placed on a Regenxbio gene therapy program.
Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.
The randomized SINGLE-AF trial, presented at ESC Congress 2026 and published in the New England Journal of Medicine, found that direct oral anticoagulants reduced serious clinical events by 69% in atrial fibrillation patients with intermediate stroke risk. The benefit was primarily driven by fewer ischemic strokes, with no increase in major bleeding.
AstraZeneca discontinued a Phase 3 trial combining its experimental bispecific antibody volrustomig with chemotherapy for lung cancer after an interim data review indicated survival goals would likely not be met. This marks another setback for the company's pipeline as it pursues an $80 billion sales target.
Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.
Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.
Skylark Bio has dosed the first patient in its SONIX Phase 1/2 trial of SKY-GJB2, a gene therapy targeting GJB2-related hearing loss, the most common genetic cause of pediatric deafness. The trial follows earlier breakthrough gene therapy treatments that restored hearing in children born deaf.
Silence Therapeutics announced that its Phase 2 SANRECO trial of divesiran met its primary endpoint in patients with polycythemia vera, a rare blood cancer, with data showing the treatment stabilized red blood cell levels and reduced phlebotomies to 0.2 per patient over 36 weeks. The company's stock rallied significantly on the news.
Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.
British researchers have conducted the first successful clinical trials of vaccines that do not require refrigeration, a breakthrough that could address the problem of half of all vaccines being discarded due to cold chain failures.
UK regulators have authorized the INTERCEPT-Lynch Phase 1/2 trial of mRNA-4194, a preventive cancer vaccine developed by Moderna and the University of Oxford targeting people with Lynch syndrome, an inherited condition affecting 1 in 300 people with up to 80% lifetime cancer risk. The trial will begin dosing in summer 2026.
Novo Nordisk's experimental inflammation-targeting drug failed to reduce the risk of heart attacks and strokes in a closely watched large clinical trial, a setback for the drugmaker's growth prospects beyond obesity and diabetes.
Latigo has announced successful mid-stage clinical trial results for its non-opioid pain medication, positioning it as a potential competitor to Vertex Pharmaceuticals' pain drug Journavx in a field historically marked by development failures.
Hansoh Pharmaceutical announced positive results from the ARTEMIS-011 Phase III trial in China, with its experimental drug Ris-Rez meeting the primary endpoint of progression-free survival in relapsed bone cancer patients. This marks the second Phase III success for the drug, strengthening GSK's oncology portfolio through its licensing partnership with the Chinese biotech.
Innocare Pharma announced its experimental oral drug for moderate-to-severe plaque psoriasis showed consistent treatment effects in late-stage clinical trials, entering a competitive market where recent head-to-head studies have compared efficacy of various psoriasis treatments.
Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.
A major U.S. clinical trial found that silver diamine fluoride, a liquid brushed onto cavities in seconds, stopped decay in more than half of treated cases. The treatment could spare many young children from pain, infection, and surgery.
Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.
The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.
GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.
The Serum Institute of India has signed an agreement with the Gates Medical Research Institute to manufacture M72/AS01E, a novel tuberculosis vaccine candidate currently in late-stage clinical trials. If approved, it would be the first new TB vaccine in over 100 years, with Serum Institute planning to invest over $100 million in production.
An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.
Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.
Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.
BeOne Medicines announced positive Phase 3 results from the MANGROVE trial, showing Brukinsa plus rituximab reduced the risk of disease progression or death by 43% compared to bendamustine plus rituximab in frontline mantle cell lymphoma patients. The combination represents a potential chemotherapy-free treatment option.
The EPCORE DLBCL-4 Phase 3 trial showed that epcoritamab (Epkinly) combined with lenalidomide significantly improved progression-free survival compared to R-GemOx chemotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. The results bring the bispecific antibody closer to a potential label expansion.
Texas-based biotech Ollin Biosciences secured $330 million in funding to advance late-stage clinical studies of its experimental eye disease treatment, representing one of the largest recent funding rounds in ophthalmology.
The United States has supplied doses of an experimental antibody drug from Mapp Biopharmaceutical to support clinical trials addressing the expanding Ebola outbreak in the Democratic Republic of Congo, according to a Health Department spokesperson.
Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.
The U.S. Food and Drug Administration announced a series of measures designed to speed up drug research across all stages, from early investigational studies through late-stage clinical trials, in an effort to compete with China and develop treatments more quickly.
The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.
The first participant has been treated in a groundbreaking clinical trial testing cellular reprogramming technology designed to rejuvenate aging cells. This marks the first time such reverse-aging therapy has been administered to a human.
AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.
ADC Therapeutics shares plunged 53% in premarket trading after a late-stage study of its blood cancer drug showed more deaths among treated patients, despite meeting its main goal. The safety signal represents a significant setback for the company's development program.
Longevity-focused biotech startup NewLimit announced a $435 million Series C funding round as it prepares to launch its first clinical trial of a liver medicine, marking one of the largest recent raises in the longevity space.
New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.
Clinical trial results show that daraxonrasib, an experimental daily pill, nearly doubled overall survival rates for patients with advanced pancreatic cancer compared to traditional chemotherapy. Medical experts are calling the results a 'game changer' for treating one of the deadliest forms of cancer.
J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.
Ivonescimab, an experimental drug combining two immunotherapy mechanisms, reduced the risk of death by 34% compared to standard immunotherapy in patients with advanced squamous non-small cell lung cancer in a closely watched Chinese trial. The drug helped patients live 15% longer than BeOne Medicines' Tevimbra.
Novartis reported early data showing its experimental actinium-based radiopharma drug demonstrated anti-tumor activity against prostate cancer, including in patients previously treated with its older therapies.
The first randomized phase 3 trial comparing radiation schedules found that delivering stereotactic radiation over three to five sessions after surgery significantly improved local control and reduced cancer recurrence at the surgical site for patients with large, resected brain metastases compared with single-fraction treatment.
Bristol Myers Squibb announced its experimental oral drug mezigdomide successfully delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to prior treatments.
Agios Pharmaceuticals announced it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show sufficient benefit, marking a setback for the rare disease program.
Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.
Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.
AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.
Five years after a disastrous trial where some boys died while others had astonishing recoveries, Astellas is returning with a revised gene therapy treatment for X-linked myotubular myopathy (XLMTM), offering new hope to a devastated rare disease community.
Johnson & Johnson's closely watched inflammatory bowel disease therapy failed to show statistically significant improvement in patients during clinical trials, representing a setback for the pharmaceutical giant's gastroenterology pipeline.
Setidegrasib, an investigational targeted therapy drug, demonstrated ability to slow cancer growth and shrink tumors in a first-in-human clinical trial published in the New England Journal of Medicine, targeting a previously difficult-to-treat cancer mutation.
A clinical trial of 108 adults with obesity and alcohol use disorder found that once-weekly semaglutide injections reduced heavy drinking days in the past 30 days by an average of roughly 12 days, representing a 50% reduction compared to placebo.
A major international clinical trial found that a minimally invasive heart procedure may be a better first-line treatment than medication for people with advanced forms of atrial fibrillation, offering improved outcomes for patients with this common heart rhythm disorder.
Two studies report that targeted, noninvasive radiation therapy (proton beam therapy) reduced episodes of life-threatening cardiac arrhythmias by nearly 80% in critically ill patients, representing the first large-scale and first-in-human evidence for this approach.
Intellia Therapeutics announced that its CRISPR-based gene editing treatment reduced swelling attacks in a pivotal trial for hereditary angioedema, a rare genetic disease. The results advance the CRISPR field's one-and-done treatment approach toward potential regulatory approval.
A major clinical trial found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin, offering evidence for expanded use of the technology beyond type 1 diabetes.
Two major clinical trials led by St. Michael's Hospital and Oxford University found that Paxlovid does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, though it helps them recover faster.
A global clinical trial found that GMRx2, a single pill combining three low-dose blood pressure medications, significantly reduced the risk of recurrent stroke in patients with intracerebral hemorrhage and high blood pressure by approximately 40%.
International clinical trial results show that gene therapy for a rare form of genetic deafness successfully restored hearing in 90% of participants, with improvements lasting years after treatment. The study was co-led by Mass General Brigham and China's Eye & ENT Hospital of Fudan University.
Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.
Kyverna Therapeutics announced plans to submit its one-time CAR-T cell therapy for stiff person syndrome to the FDA after late-stage trial showed improvements in mobility and reduced disabilities in patients with the rare neurological disease.
Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.
BioAge Labs announced its investigational pill for cardiovascular risk prevention significantly reduced inflammation markers in an early-stage clinical study, representing potential progress in heart disease prevention.
Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.
A landmark trial presented at ESCMID Global 2026 demonstrates that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia by 60%, offering a simple intervention to prevent a serious complication.
India has approved new tuberculosis vaccines for adolescents, backed by a large, independent Phase III clinical trial led and funded by public science institutions. The vaccines represent a significant breakthrough in TB prevention, though officials note they are not a complete solution.
UPMC and University of Pittsburgh researchers successfully weaned multiple liver transplant patients off all immunosuppressant drugs for over three years using a pre-transplant cell therapy approach, representing a potential breakthrough in organ transplantation.
Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.